Azala

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER

Objectives: Capecitabine is an oral fluoropyrimidine carbamate that is at least as effective than Fluorouracil / Leucovorin as first- line treatment for patients with metastatic colorectal cancer /CRC/. The topoisomerase I inhibitor Irinotecan has shown consistent efficacy in chemotherapy- naive pat...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Deyan Davidov (Egilea)
Formatua:	Liburua
Argitaratua:	Peytchinski Publishing, 2010-11-01T00:00:00Z.
Gaiak:	article
Sarrera elektronikoa:	Connect to this object online.
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
nork: Deyan Davidov
Argitaratua: (2008)

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA
nork: Deyan Davidov
Argitaratua: (2014)

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST - LINE CHEMOTHERAPY
nork: Deyan Davidov
Argitaratua: (2017)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
nork: Suenaga M, et al.
Argitaratua: (2015)

OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
nork: Deyan N. Davidov
Argitaratua: (2013)

THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
nork: Deyan Davidov
Argitaratua: (2014)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
nork: Deyan N. Davidov
Argitaratua: (2013)

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
nork: Deyan Davidov
Argitaratua: (2016)

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
nork: Deyan N. Davidov
Argitaratua: (2013)

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the US
nork: Victoria Federico Paly, et al.
Argitaratua: (2024)

Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters
nork: Esther Oyaga-Iriarte, et al.
Argitaratua: (2019)

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES
nork: Assia Konsoulova, et al.
Argitaratua: (2016)

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
nork: Deyan Davidov
Argitaratua: (2010)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
nork: Pau Riera, et al.
Argitaratua: (2020)

A Case of Long Term Survival in Woman with Metastatic Breast Cancer Treated with Trastuzumab
nork: Deyan N. Davidov
Argitaratua: (2012)

Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients
nork: Saeed Alqahtani, et al.
Argitaratua: (2022)

The effective combination therapies with irinotecan for colorectal cancer
nork: Yun Chai, et al.
Argitaratua: (2024)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
nork: Jia X, et al.
Argitaratua: (2023)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
nork: Toshiki Masuishi, et al.
Argitaratua: (2023)

Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report
nork: Mingming Li, et al.
Argitaratua: (2019)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
nork: Mashiro Okunaka, et al.
Argitaratua: (2021)

Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines
nork: Mahshid Mohammadian, et al.
Argitaratua: (2017)

Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
nork: Lakshmi Chintala, et al.
Argitaratua: (2011)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
nork: Zhengda Pei, et al.
Argitaratua: (2023)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer
nork: Karl Brendel, et al.
Argitaratua: (2021)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
nork: Jinwei Zhu, et al.
Argitaratua: (2023)

Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer
nork: Julia Sánchez-Gundín, et al.
Argitaratua: (2019)

Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients
nork: Emel Emine Kayikci, et al.
Argitaratua: (2020)

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L
nork: Adrien Labriet, et al.
Argitaratua: (2017)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
nork: Bei Yue, et al.
Argitaratua: (2021)

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis
nork: Shuzhen Liu, et al.
Argitaratua: (2022)

GEMCITABINE / PLATINUM VS. VINORELBINE- PLATINUM IN PATIENTS WITH ADVANCED NON- SMALL- CELL LUNG CANCER
nork: Deyan Davidov
Argitaratua: (2008)

Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients
nork: Yasmin Cura, et al.
Argitaratua: (2023)

Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer
nork: Mulan Chen, et al.
Argitaratua: (2024)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
nork: Tan Chongqing, et al.
Argitaratua: (2021)

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
nork: Atlal eAbu-Sanad, et al.
Argitaratua: (2015)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
nork: Xiaoyan Liu, et al.
Argitaratua: (2022)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
nork: Meiyu Fang, et al.
Argitaratua: (2012)

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
nork: Zuojuan Xiang, et al.
Argitaratua: (2024)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis
nork: Zilin Zhang, et al.
Argitaratua: (2021)